Latest / Glaucoma, Vision & Longevity: Supplements & Science / Glaucoma Drainage Implants in Midlife: Decoding the Long-Term Success Rates

Transcript

Glaucoma Drainage Implants in Midlife: Decoding the Long-Term Success Rates · Glaucoma, Vision & Longevity: Supplements & Science

• 0:00
  SPEAKER_00: Glaucoma drainage implants in midlife, decoding the long-term success rates.
• 0:04
  SPEAKER_00: Glaucoma drainage implants, also called aqueous shunts or tube shunts, are filters placed in the eye to lower pressure by draining excess fluid.
• 0:13
  SPEAKER_00: They are often used when standard surgery, trabeculectomy, is unlikely to succeed or has already failed.
• 0:20
  SPEAKER_00: Common devices include the omid glaucoma valve, a valved implant, the bare velt glaucoma implant, a larger nonvalved plate, and the older Molteno implant.
• 0:30
  SPEAKER_00: Newer, minimally invasive options, like the Zen stent or Preserflow microshunt exist, but they are generally for milder cases and have less long-term data.
• 0:40
  SPEAKER_00: Trabeculectomy is the classic glaucoma surgery that creates a new drain in the eye without a device.
• 0:46
  SPEAKER_00: A thin flap is made and often treated with an agent, mitomycin C, to prevent scarring.
• 0:51
  SPEAKER_00: By contrast, a tube implant has an artificial tube leading to a small reservoir, plate, under the eye's surface.
• 0:58
  SPEAKER_00: In effect, both aim to create a bleb, a drainage pocket, but trabeculectomy relies on the body's tissues alone, whereas a tube shunt uses foreign material.
• 1:08
  SPEAKER_00: Each approach has pros and cons.
• 1:10
  SPEAKER_00: Tubes usually are chosen when trabeculectomy may fail, for example, if the conjunctiva is scarred or in some secondary glaucomas.
• 1:18
  SPEAKER_00: Studies often compare tube shunts versus trabeculectomy head to head because both lower pressure but with different mechanisms and healing tendencies.
• 1:28
  SPEAKER_00: Defining success and failure.
• 1:30
  SPEAKER_00: How do researchers judge success after glaucoma surgery?
• 1:35
  SPEAKER_00: There is no single definition, so results can look different across studies.
• 1:39
  SPEAKER_00: In general, complete success means the eye pressure is controlled without any glaucoma medications and remains in a safe range.
• 1:47
  SPEAKER_00: For example, 1 or 21 millimeter hergrams, often with at least a 20% drop from baseline.
• 1:52
  SPEAKER_00: We measure pressure with IOP, intraocular pressure.
• 1:56
  SPEAKER_00: The exact target varies.
• 1:57
  SPEAKER_00: Some studies use 18 millimeter hergrams, some to 21 mm hergrabs, for instance.
• 2:03
  SPEAKER_00: Common practice is to say IOP in the mid-teens or below is a success if it's stable.
• 2:08
  SPEAKER_00: Qualified success allows glaucoma medicines.
• 2:11
  SPEAKER_00: In this case, the IOP is still in the target range, but the patient is using eye drops or pills in addition to the surgery.
• 2:17
  SPEAKER_00: Failure is defined when the pressure is too high, above the chosen cutoff, or not lowered enough, less than the required percentage drop, or if another glaucoma procedure becomes necessary.
• 2:29
  SPEAKER_00: Some definitions also count vision loss, e.g., loss of light perception, or serious complications, like uncontrollable hypotany, as failure.
• 2:39
  SPEAKER_00: In short, failure generally means the surgery did not solve the problem on its own.
• 2:44
  SPEAKER_00: Because different researchers picked different pressure goals, success rates can't be compared directly unless the definitions match.
• 2:51
  SPEAKER_00: For example, some trials counted any IOP up to 21 mmHg grams as success, while others needed Tunch 18 mmHg.
• 2:59
  SPEAKER_00: It is important to note whether a reported success rate was complete, no meds, or qualified with meds.
• 3:04
  SPEAKER_00: Many papers report both when data is available.
• 3:07
  SPEAKER_00: Long-term outcomes.
• 3:09
  SPEAKER_00: What do the numbers show?
• 3:10
  SPEAKER_00: Tube shunts versus trabeculectomy, TVT study.
• 3:13
  SPEAKER_00: The landmark tube versus trabeculectomy, TVT, study was a randomized trial that followed patients for five years.
• 3:20
  SPEAKER_00: It compared the bare velt tube 350 mm plate to trabeculectomy with mitomycin.
• 3:25
  SPEAKER_00: Key findings at five years, 212 eyes were pressure control, both groups had similar final IOP around mid-teens and a similar drop in medication use.
• 3:35
  SPEAKER_00: Success, no failure, rate, 70.2% in the tube group versus 53.1% in the trabeculectomy group at five years.
• 3:44
  SPEAKER_00: In other words, failure, meeting failure criteria, had occurred in 29.8% of tubes and 46.9% of TRAB outcomes, P equals 0.002, showing tubes held pressure more reliably over time.
• 3:57
  SPEAKER_00: Reoperation, additional glaucoma surgery was needed much less often in the tube group, 9% versus 29% in the trabeculectomy group at five years.
• 4:07
  SPEAKER_00: These results suggest that after five years, a tube shunt was more likely to maintain target pressure than trabecbeculectomy in this study, for eyes that had prior cataract or trab surgery history.
• 4:19
  SPEAKER_00: The IOP reduction achieved by both surgeries was similar, but trabeculectomy more often required repeat surgery.
• 4:26
  SPEAKER_00: Even at three years of follow-up, the study showed cumulative failure rates of 15.1% for tubes versus 30.7% for trabeculectomy, i.e.
• 4:36
  SPEAKER_00: 84.9% versus 69.3% success at three years.
• 4:40
  SPEAKER_00: In practical terms, the TVT study implies that about 30-40% of tube shunts may fail or need reoperation within 5 years, whereas trabeculectomy failure was around 47% in that time frame.
• 4:53
  SPEAKER_00: Note, failure here includes not only high pressure but also tube removal, vision loss, or need for more surgery.
• 4:59
  SPEAKER_00: The pattern seen was about a 5% failure per year for tubes.
• 5:03
  SPEAKER_00: So roughly half survive at 10 years, see below.
• 5:07
  SPEAKER_00: Ahmed valve versus barevelt implant, AVB and ABC studies.
• 5:11
  SPEAKER_00: Several trials have directly compared the Ahmed valve Ahmed FP7 to the barevelt implant, BGI.
• 5:17
  SPEAKER_00: Both designs are common and understanding their long-term outcomes is important.
• 5:21
  SPEAKER_00: Briefly, Ahmed FP7 has a built-in valve that resists very low pressure, so-called flow restricting valve.
• 5:28
  SPEAKER_00: It often lowers IOP quickly, but may allow higher long-term pressures.
• 5:33
  SPEAKER_00: Barevelt non-valved relies on a temporary ligature until tissue capsule forms.
• 5:38
  SPEAKER_00: It can achieve lower pressures but sometimes carries a small risk of low pressure complications, hypotony, once the ligature dissolves.
• 5:46
  SPEAKER_00: Key study findings at three and five years, several hundred eyes combined.
• 5:51
  SPEAKER_00: Three-year outcomes, the AVB, AMED vs.
• 5:53
  SPEAKER_00: barevelt.
• 5:54
  SPEAKER_00: Study reported that at three years, the cumulative failure rate was 51% with AMED versus 34% with barevelt, P.03.
• 6:03
  SPEAKER_00: Mean IOP was slightly lower in barevelt eyes, 14.4 mmhergrams, than AMED, 15.7 mm, and Berevelt eyes needed fewer medications, 1.1.8 p equals 0002.
• 6:15
  SPEAKER_00: Complication rates were similar, though hypotony-related issues were more common with barevelt.
• 6:21
  SPEAKER_00: Five-year outcomes, ADB study.
• 6:24
  SPEAKER_00: In a later five-year report, the AVB trial showed five-year failure of 53% with AMED and 40% with barevelt, significantly favoring Beervelt, P equals 0.04.
• 6:34
  SPEAKER_00: The average IOP at five years was 16.6 millimeter gramid versus 13.6 millimeter HRM barevelt, and final medication use was 1.8 versus 1.2 drops.
• 6:44
  SPEAKER_00: Hypoteny failures were 0% in AMID versus 4% in barevelt, since only the non-valved can overdrain.
• 6:50
  SPEAKER_00: Five-year outcomes ABC study, the ABC Bearvelt Comparison Study, a different multi-center trial, found a five-year failure rate of 44.7%, AMID versus 39.4% barevelt, not statistically different, p equals 0.65.
• 7:05
  SPEAKER_00: At 5 years, the IOP was 14.7 mmHg AMED versus 12.7 mm barevelt, with about 2.2 versus 1.8 medications.
• 7:15
  SPEAKER_00: Putting it together, most trials show moderately better control with the barevelt implant.
• 7:20
  SPEAKER_00: Roughly half of AMED valves and about 40% of barevelt implants may fail by five years, meaning about half are still successful at that point.
• 7:29
  SPEAKER_00: The differences aren't enormous, but generally barevelt tends to reach lower pressures and needs slightly fewer pills at the cost of a little more risk of very low pressure.
• 7:39
  SPEAKER_00: Overall success rates, complete or qualified at five years, are on the order of 45 to 60%, depending on the study and definition.
• 7:47
  SPEAKER_00: For example, if failure is 40%, success is 60%.
• 7:52
  SPEAKER_00: Other implants.
• 7:53
  SPEAKER_00: The Molteno implant is an older design, non-valved.
• 7:56
  SPEAKER_00: Long-term data is sparser, but historical series suggest intermediate success rates, roughly similar ballpark as Barevelt.
• 8:04
  SPEAKER_00: Since its design is similar to Bearvelt, just smaller plate per stage, we treat it similarly, but it is not commonly used today.
• 8:11
  SPEAKER_00: Newer, minimally invasive implants, e.g., XN gel stent, preserflow micro shunt, are smaller tubes placed via AB interno approach.
• 8:21
  SPEAKER_00: These have been marketed in the last decade but have less long-term evidence.
• 8:25
  SPEAKER_00: Early results indicate they can lower IOP, but often not as much as traditional tubes, and they may still fail over time.
• 8:33
  SPEAKER_00: For our purposes focused on long-term outcomes, the traditional AMED and barevelt implants provide the bulk of data.
• 8:40
  SPEAKER_00: Age and device survival, middle-age versus older patients.
• 8:44
  SPEAKER_00: Age can influence healing.
• 8:46
  SPEAKER_00: Younger eyes tend to heal more vigorously and scar more, which can cause drainage surgery to fail sooner.
• 8:52
  SPEAKER_00: Indeed, analyses from large trials confirm younger age is a risk factor for failure of tube shunts.
• 8:58
  SPEAKER_00: In a pooled study of hundreds of patients from major trials, TVT, AVB, ABC, each 10-year decrease in age raised failure risk by about 19%.
• 9:09
  SPEAKER_00: In simpler terms, for example, a 50-year-old tended to have better success than a 40-year-old with the same surgery.
• 9:15
  SPEAKER_00: This mirrors findings in trabeculectomy.
• 9:18
  SPEAKER_00: Younger patients generally scar faster, undermining the bleb.
• 9:22
  SPEAKER_00: However, most published trials have mean ages in the 60s or higher.
• 9:26
  SPEAKER_00: There is very little data specifically on 35 to 55-year-olds.
• 9:31
  SPEAKER_00: We extrapolate from the broader studies.
• 9:33
  SPEAKER_00: Overall, middle-aged adults, e.g., 40-year-olds, may be somewhat more prone to failure than the typical study participant who might be retired and in their 70s.
• 9:44
  SPEAKER_00: But the exact drop in success isn't sorted out in age subgroups in the literature.
• 9:49
  SPEAKER_00: Clinically, surgeons worry that a 40-year-old's robust healing will encapsulate the plate sooner, so we tend to expect somewhat lower long-term success in midlife than in an older person.
• 10:00
  SPEAKER_00: No landmark trial explicitly reports a 40-year-old subgroup, so we rely on risk factor analyses rather than head-to-head age comparisons.
• 10:10
  SPEAKER_00: In summary, younger patients, including those in their 40s, generally have a higher rate of scarring and failure after any glaucoma surgery.
• 10:19
  SPEAKER_00: This is cited in the literature, but the decline in success with midlife age is a bit hard to quantify precisely.
• 10:26
  SPEAKER_00: We certainly advise they will likely require more follow-up and possible additional surgeries over time.
• 10:32
  SPEAKER_00: Glaucoma type also matters.
• 10:34
  SPEAKER_00: Not all glaucomas are equally likely to respond to drainage surgeries.
• 10:38
  SPEAKER_00: Most major trials mix various types or focus on open angle glaucoma, but many eyes had other causes.
• 10:45
  SPEAKER_00: In general, primary open angle glaucoma, POEC, the most common adult glaucoma, tends to do decently with tubes.
• 10:52
  SPEAKER_00: These patients are usually the subjects of trials, and success rates above apply.
• 10:57
  SPEAKER_00: Neovascular glaucoma, NVG, from diabetes or ischemic eye disease is the toughest.
• 11:03
  SPEAKER_00: NVG eyes form scar tissue very aggressively.
• 11:06
  SPEAKER_00: In pooled analyses, neovascular glaucoma was a significant risk factor for failure, hazard ratio 1.8.
• 11:13
  SPEAKER_00: In practice, success with NVG is often much lower than typical.
• 11:16
  SPEAKER_00: Many devices fail early.
• 11:18
  SPEAKER_00: UVatic glaucoma from eye inflammation is also a high-risk situation.
• 11:23
  SPEAKER_00: Studies, including meta-analyses, show that drainage implants do work, but outcomes are generally worse than POAG.
• 11:30
  SPEAKER_00: For example, one review found pressure reductions were similar between uveatic and non-uveatic eyes, but uveatic eyes often needed more interventions for complications, like inflammation-related issues.
• 11:42
  SPEAKER_00: We lack a clean percentage, but surgeons know these eyes scar readily and require close monitoring.
• 11:48
  SPEAKER_00: Pigmentary, pseudoexfoliation, traumatic juvenile, data is thinner.
• 11:53
  SPEAKER_00: Pigmentary and pseudoexfoliation, secondary open angle, likely behave somewhat like POIG, maybe slightly higher scarring risk.
• 12:01
  SPEAKER_00: Traumatic glaucoma could be very variable, depends on angle injury.
• 12:05
  SPEAKER_00: Congenital or juvenile glaucomas carried into adulthood are rare.
• 12:09
  SPEAKER_00: They are known to scar profusely.
• 12:11
  SPEAKER_00: Since most studies combine all types, precise success rates by subtype are not well quantified.
• 12:17
  SPEAKER_00: We can say secondary glaucoma, uveitic, neovascular, tend to do worse.
• 12:21
  SPEAKER_00: Indeed, in the pooled risk analysis, conditions like neovascular and high preop pressure predicted lower success.
• 12:28
  SPEAKER_00: In contrast, classic POEG in an older adult had among the best outcomes.
• 12:33
  SPEAKER_00: An important takeaway for a 40-year-old, the underlying glaucoma cause matters at least as much as age, complications, and need for more surgery.
• 12:42
  SPEAKER_00: A vital part of any glaucoma surgery discussion, what problems can occur and how often might further operations be needed.
• 12:50
  SPEAKER_00: Drainage devices have unique long-term complications.
• 12:54
  SPEAKER_00: Key points.
• 12:55
  SPEAKER_00: Corneal damage.
• 12:56
  SPEAKER_00: Most concerning is the risk of losing corneal clarity.
• 12:59
  SPEAKER_00: Over time, the tube can touch or be close to the inner cornea, causing cell loss.
• 13:04
  SPEAKER_00: Studies show significant endothelial cell loss with GDDs.
• 13:08
  SPEAKER_00: One study found an average 8% loss of central cells at 6 months and 12.6% at 12 months after AMED valve surgery.
• 13:16
  SPEAKER_00: Over years, this can lead to corneal decompensation, persistent corneal swelling.
• 13:21
  SPEAKER_00: One long-term series, mostly AMED FP7, reported corneal decompensation in 19% of eyes during follow-up.
• 13:28
  SPEAKER_00: In other words, roughly 1 in 5 eyes eventually developed corneal failure requiring a transplant.
• 13:35
  SPEAKER_00: In the same series, five eyes actually lost sight from complications.
• 13:40
  SPEAKER_00: Patients should be told a tube might control pressure but could risk the clear window of the eye decades later.
• 13:46
  SPEAKER_00: Tube or plate exposure.
• 13:48
  SPEAKER_00: The conjunctival cover over the device can erode.
• 13:51
  SPEAKER_00: One study found about 5.8% of shunts eventually became exposed through the eyelids lining.
• 13:57
  SPEAKER_00: This is dangerous because exposure often leads to infection.
• 14:01
  SPEAKER_00: In fact, tube exposure is the number one risk factor for endophthalmitis, infection inside the eye.
• 14:07
  SPEAKER_00: Infection rates reported after GDD range from 0.8% to around 6%, averaging about 2%.
• 14:13
  SPEAKER_00: In short, roughly 2-6% of eyes may get a serious infection years after a drainage implant, almost always related to exposure.
• 14:21
  SPEAKER_00: Many times these exposures occur around 1 to 3 years after surgery, but can be as late as 5 to 10 years.
• 14:29
  SPEAKER_00: Diplopia, double vision.
• 14:31
  SPEAKER_00: When a large plate is sutured under the eye muscles, it can slightly alter eye alignment or movement.
• 14:36
  SPEAKER_00: Double vision is an under-discussed but real problem.
• 14:40
  SPEAKER_00: In one series, about 31% of patients with a bare belt 350 implant, the larger 350 mm squared plate, reported new diplopia attributable to the surgery, compared to TOR 13% with AMED FP7, smaller plate.
• 14:54
  SPEAKER_00: Another prospective study, TVT ABC combined data, found diplopia in about 3-5% of cases, but that likely underestimates it due to incomplete testing.
• 15:04
  SPEAKER_00: The takeaway, diplopia is not rare, especially with bigger devices or multiple tubes.
• 15:09
  SPEAKER_00: Patients often do adapt or it can be managed, but it's an important counseling point.
• 15:14
  SPEAKER_00: Hypotony, very low pressure.
• 15:16
  SPEAKER_00: Over drainage can lead to low IOP, which can damage the eye, choroidal detachments, vision loss.
• 15:22
  SPEAKER_00: Valved implants MOD rarely cause true hypotany.
• 15:25
  SPEAKER_00: Nonvalved ones, barevelt molteno, have a small but real risk of late hypotony once the ligature dissolves.
• 15:31
  SPEAKER_00: In the AVB study, 4% of barevelt eyes failed due to hypotony versus 0% of AMED eyes.
• 15:37
  SPEAKER_00: In a clinical series, about 4.5% of eyes had chronic hypotony post-GDD.
• 15:43
  SPEAKER_00: Other issues.
• 15:44
  SPEAKER_00: Many eyes develop encapsulated blebs around the plate.
• 15:47
  SPEAKER_00: In one report, 24.5% were noted to have a thick capsule restricting flow.
• 15:53
  SPEAKER_00: Tube obstruction by iris, blood, or debris occurs rarely, a few percent.
• 15:58
  SPEAKER_00: Retinal detachments or severe vision loss thesis are uncommon, 3 to 4% each in one series.
• 16:05
  SPEAKER_00: Additional surgeries.
• 16:07
  SPEAKER_00: Probably the single biggest concern for a younger patient, how many surgeries will I need?
• 16:11
  SPEAKER_00: All the above complications and gradual failure mean that multiple surgeries are common over a lifetime.
• 16:17
  SPEAKER_00: For example, the TVT study, Tube vs.
• 16:20
  SPEAKER_00: TRAB, reported reoperation for glaucoma in 9% of tube eyes within five years.
• 16:25
  SPEAKER_00: In the Ahmed v.
• 16:26
  SPEAKER_00: Bearveld trials, 11 to 18% had another glaucoma surgery by five years.
• 16:31
  SPEAKER_00: In one retrospective series of 110 GDD eyes, mostly Ahmed FP7, the average number of additional glaucoma procedures was 1.5, ranged 0 to 6 over the follow-up.
• 16:41
  SPEAKER_00: In that report, 27 of 110 eyes, 24.5%, needed bleb needling or 5FU injections to reopen flow, 16 eyes, 14.5% needed tube reshaping or shortening, 12 eyes, 10.9% eventually got a second GDD, and 17 eyes, 15.4% underwent cyclophotocoagulation, laser ciliary body destruction.
• 17:04
  SPEAKER_00: Some even required cataract surgery or retinal surgeries.
• 17:08
  SPEAKER_00: In total, 56% of eyes had at least one complication, and many required additional surgeries.
• 17:14
  SPEAKER_00: In plain language, expect the unexpected.
• 17:17
  SPEAKER_00: Even if the shunt initially controls pressure, there is a significant chance, perhaps 20 to 50% over many years, it will fail or cause trouble, requiring another intervention.
• 17:28
  SPEAKER_00: Patients and doctors should plan for long-term management, not a one-time cure, especially for younger patients with decades ahead.
• 17:35
  SPEAKER_00: The Longview, a 40-year-old versus an elderly patient.
• 17:39
  SPEAKER_00: Why does age change the calculus?
• 17:42
  SPEAKER_00: Simply put, a 75-year-old patient might need good control for 5 to 10 years more, whereas a 40-year-old may need 30 to 40 more years of glaucoma management.
• 17:52
  SPEAKER_00: Even a 5% per year failure rate adds up.
• 17:56
  SPEAKER_00: At 5% per year, about 50% of shunts fail by 10 years.
• 18:01
  SPEAKER_00: In one 10-year series, roughly one half of tube surgeries were still successful at 10 years, meaning the other half had failed or needed retreatment.
• 18:10
  SPEAKER_00: This implies a 40-year-old is very likely to outlive a single implant.
• 18:15
  SPEAKER_00: Realistically, such a patient may go through multiple procedures over time, maybe a new shunt or other surgery every decade or so, depending on results.
• 18:24
  SPEAKER_00: Each surgery carries its own risks and burns through the limited surgical lifetime of the eye's tissues.
• 18:31
  SPEAKER_00: By contrast, an 80-year-old might get by with one shunt and live the rest of life with it.
• 18:37
  SPEAKER_00: In practice, when counseling a 40-something patient, doctors stress that tubing is often one step in a lifetime of glaucoma care.
• 18:46
  SPEAKER_00: It is usually not permanent.
• 18:48
  SPEAKER_00: We might say, this implant has a roughly 50% chance to keep working at 10 years, so you may well need another surgery later, but all surgeries we have combined are aimed at preserving vision for decades.
• 19:02
  SPEAKER_00: In summary, the take-home is younger patients face a different risk profile.
• 19:08
  SPEAKER_00: The same implant that works well for 5 years in a 70-year-old has to keep working for 30 to 40 years in a 40-year-old.
• 19:15
  SPEAKER_00: No published data guarantees any one shunt will last that long.
• 19:19
  SPEAKER_00: We rely on averages from older populations.
• 19:22
  SPEAKER_00: Thus, a 40-year-old and their surgeon should plan on close follow-up and have backup plans, other surgeries, lasers, medications for the future.
• 19:31
  SPEAKER_00: Conclusion.
• 19:32
  SPEAKER_00: Drainage implants, Ahmed Beerveld, etc., are effective ways to lower eye pressure long term, and they often outperform trabeculectomy in maintaining pressure over five years.
• 19:43
  SPEAKER_00: On average, about 50 to 60% of shunts remain successful at five years, but that falls to roughly 50% by 10 years.
• 19:51
  SPEAKER_00: Success is defined by reaching a target IOP, often 18 to 21 mNograms with or without medications.
• 19:59
  SPEAKER_00: Age matters.
• 20:00
  SPEAKER_00: Younger, midlife eyes tend to scar more, and studies confirm younger patients have higher failure rates.
• 20:07
  SPEAKER_00: Therefore, a patient around 40 should expect a somewhat lower long-term survival of a single shunt than an older patient.
• 20:14
  SPEAKER_00: Glaucoma subtype also matters.
• 20:16
  SPEAKER_00: Secondary glaucomas like neovascular or uveatic generally do more poorly, whereas primary open-angle glaucoma is most studied and fares better on average.
• 20:26
  SPEAKER_00: All surgery carries risks.
• 20:28
  SPEAKER_00: The notable complications of tube implants include corneal damage, with 10 to 20% of eyes affected over time, device erosion, 5% chance, leading to infection, towards a 2% risk, double vision, seen in up to 30% with large plates, and over drainage on the order of a few percent.
• 20:49
  SPEAKER_00: In one study, more than half the patients had some adverse event, and the average eye needed over one extra glaucoma surgery in the years that followed.
• 20:58
  SPEAKER_00: The bottom line a glaucoma shunt can buy many years of vision by lowering eye pressure, but it is rarely a set it and forget it solution in a 40-year-old.
• 21:08
  SPEAKER_00: Patients should be prepared for a lifelong management plan.
• 21:11
  SPEAKER_00: A single shunt is usually one step in a sequence of therapies.
• 21:15
  SPEAKER_00: The data we have, in large part from older patients, show robust midterm success, but also make it clear that failure accumulates over time.
• 21:24
  SPEAKER_00: Currently, there are no large studies focused exclusively on middle-aged patients to give a precise number just for 35 to 55 years, so we apply what we know from broader studies and clinical experience.
• 21:36
  SPEAKER_00: For now, we tell midlife patients that tube shunts work well initially, but can fail over decades.
• 21:43
  SPEAKER_00: A young adult will likely need additional interventions eventually.
• 21:47
  SPEAKER_00: We encourage them to stay engaged with their eye care, watch for signs of pressure rise or complications, and maintain a plan to preserve vision over the very long term.
• 21:57
  SPEAKER_00: References.
• 21:58
  SPEAKER_00: Major findings above are supported by clinical trials and reviews, among others.
• 22:03
  SPEAKER_00: Where possible, we cite large multi-center studies, e.g.
• 22:07
  SPEAKER_00: TVT, AVB, ABC, and systematic analyses to ensure the data is reliable.
• 22:12
  SPEAKER_00: Any single center or smaller reports are noted only if they provide unique insights.
• 22:17
  SPEAKER_00: Tags glaucoma surgery, glaucoma drainage device, tube shunt outcomes, Ahmed valve versus Bearvelt, long-term glaucoma treatment, middle aged glaucoma patients, trabeculectomy comparison, device complications.
• 22:30
  SPEAKER_00: All links to sources are available in the text version of this article.
• 22:34
  SPEAKER_00: You can find the full article at VisualFieldTest.com.
• 22:38
  SPEAKER_00: Thanks for listening.
• 22:40
  SPEAKER_00: To check your visual field, click the link at the bottom of this article or visit VisualFieldTest.com.